Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Spol 15 sekunder tilbage
Spol 15 sekunder frem
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

Flere episoder fra "Pharmaceutical Executive"